Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for BMRN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 1999. Start Trial.
Date Value
June 30, 2026 4.186B
March 31, 2026 1.440B
December 31, 2025 634.30M
September 30, 2025 604.24M
June 30, 2025 596.16M
March 31, 2025 601.96M
December 31, 2024 626.74M
September 30, 2024 602.69M
June 30, 2024 1.100B
March 31, 2024 1.097B
December 31, 2023 1.125B
September 30, 2023 1.086B
June 30, 2023 1.085B
March 31, 2023 1.084B
December 31, 2022 1.112B
September 30, 2022 1.082B
June 30, 2022 1.081B
March 31, 2022 1.080B
December 31, 2021 1.115B
September 30, 2021 1.078B
June 30, 2021 1.077B
March 31, 2021 1.076B
December 31, 2020 1.122B
September 30, 2020 1.497B
June 30, 2020 1.493B
Date Value
March 31, 2020 906.34M
December 31, 2019 902.17M
September 30, 2019 901.61M
June 30, 2019 895.93M
March 31, 2019 885.58M
December 31, 2018 830.42M
September 30, 2018 1.200B
June 30, 2018 1.192B
March 31, 2018 1.183B
December 31, 2017 1.174B
September 30, 2017 1.166B
June 30, 2017 676.20M
March 31, 2017 690.93M
December 31, 2016 683.24M
September 30, 2016 675.64M
June 30, 2016 670.10M
March 31, 2016 668.01M
December 31, 2015 662.29M
September 30, 2015 667.79M
June 30, 2015 661.49M
March 31, 2015 655.49M
December 31, 2014 657.98M
September 30, 2014 656.88M
June 30, 2014 650.87M
March 31, 2014 661.42M

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 2.942B
Incyte Corp. 32.68M
Vertex Pharmaceuticals, Inc. 1.978B
BridgeBio Pharma, Inc. 3.370B
Ionis Pharmaceuticals, Inc. 2.189B